Copyright Reports & Markets. All rights reserved.

Global and United States Bivalent Human Papillomavirus Vaccine Market Report & Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Bivalent Human Papillomavirus Vaccine Product Introduction
    • 1.2 Global Bivalent Human Papillomavirus Vaccine Outlook 2017 VS 2022 VS 2028
      • 1.2.1 Global Bivalent Human Papillomavirus Vaccine Sales in US$ Million for the Year 2017-2028
      • 1.2.2 Global Bivalent Human Papillomavirus Vaccine Sales in Volume for the Year 2017-2028
    • 1.3 United States Bivalent Human Papillomavirus Vaccine Outlook 2017 VS 2022 VS 2028
      • 1.3.1 United States Bivalent Human Papillomavirus Vaccine Sales in US$ Million for the Year 2017-2028
      • 1.3.2 United States Bivalent Human Papillomavirus Vaccine Sales in Volume for the Year 2017-2028
    • 1.4 Bivalent Human Papillomavirus Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028
      • 1.4.1 The Market Share of United States Bivalent Human Papillomavirus Vaccine in Global, 2017 VS 2022 VS 2028
      • 1.4.2 The Growth Rate of Bivalent Human Papillomavirus Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028
    • 1.5 Bivalent Human Papillomavirus Vaccine Market Dynamics
      • 1.5.1 Bivalent Human Papillomavirus Vaccine Industry Trends
      • 1.5.2 Bivalent Human Papillomavirus Vaccine Market Drivers
      • 1.5.3 Bivalent Human Papillomavirus Vaccine Market Challenges
      • 1.5.4 Bivalent Human Papillomavirus Vaccine Market Restraints
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Market by Type

    • 2.1 Bivalent Human Papillomavirus Vaccine Market Segment by Type
      • 2.1.1 HPV16
      • 2.1.2 HPV18
    • 2.2 Global Bivalent Human Papillomavirus Vaccine Market Size by Type
      • 2.2.1 Global Bivalent Human Papillomavirus Vaccine Sales in Value, by Type (2017, 2022 & 2028)
      • 2.2.2 Global Bivalent Human Papillomavirus Vaccine Sales in Volume, by Type (2017, 2022 & 2028)
      • 2.2.3 Global Bivalent Human Papillomavirus Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    • 2.3 United States Bivalent Human Papillomavirus Vaccine Market Size by Type
      • 2.3.1 United States Bivalent Human Papillomavirus Vaccine Sales in Value, by Type (2017, 2022 & 2028)
      • 2.3.2 United States Bivalent Human Papillomavirus Vaccine Sales in Volume, by Type (2017, 2022 & 2028)
      • 2.3.3 United States Bivalent Human Papillomavirus Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028)

    3 Market by Application

    • 3.1 Bivalent Human Papillomavirus Vaccine Market Segment by Application
      • 3.1.1 9-16 Years Old
      • 3.1.2 16-20 Years Old
      • 3.1.3 20-26 Years Old
      • 3.1.4 26-45 Years Old
    • 3.2 Global Bivalent Human Papillomavirus Vaccine Market Size by Application
      • 3.2.1 Global Bivalent Human Papillomavirus Vaccine Sales in Value, by Application (2017, 2022 & 2028)
      • 3.2.2 Global Bivalent Human Papillomavirus Vaccine Sales in Volume, by Application (2017, 2022 & 2028)
      • 3.3.3 Global Bivalent Human Papillomavirus Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    • 3.3 United States Bivalent Human Papillomavirus Vaccine Market Size by Application
      • 3.3.1 United States Bivalent Human Papillomavirus Vaccine Sales in Value, by Application (2017, 2022 & 2028)
      • 3.3.2 United States Bivalent Human Papillomavirus Vaccine Sales in Volume, by Application (2017, 2022 & 2028)
      • 3.3.3 United States Bivalent Human Papillomavirus Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028)

    4 Global Bivalent Human Papillomavirus Vaccine Competitor Landscape by Company

    • 4.1 Global Bivalent Human Papillomavirus Vaccine Market Size by Company
      • 4.1.1 Top Global Bivalent Human Papillomavirus Vaccine Manufacturers Ranked by Revenue (2021)
      • 4.1.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Manufacturer (2017-2022)
      • 4.1.3 Global Bivalent Human Papillomavirus Vaccine Sales by Manufacturer (2017-2022)
      • 4.1.4 Global Bivalent Human Papillomavirus Vaccine Price by Manufacturer (2017-2022)
    • 4.2 Global Bivalent Human Papillomavirus Vaccine Concentration Ratio (CR)
      • 4.2.1 Bivalent Human Papillomavirus Vaccine Market Concentration Ratio (CR) (2017-2022)
      • 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Bivalent Human Papillomavirus Vaccine in 2021
      • 4.2.3 Global Bivalent Human Papillomavirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 4.3 Global Bivalent Human Papillomavirus Vaccine Manufacturing Base Distribution, Product Type
      • 4.3.1 Global Bivalent Human Papillomavirus Vaccine Manufacturers, Headquarters and Distribution of Producing Region
      • 4.3.2 Manufacturers Bivalent Human Papillomavirus Vaccine Product Type
      • 4.3.3 Date of International Manufacturers Enter into Bivalent Human Papillomavirus Vaccine Market
    • 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    • 4.5 United States Bivalent Human Papillomavirus Vaccine Market Size by Company
      • 4.5.1 Top Bivalent Human Papillomavirus Vaccine Players in United States, Ranked by Revenue (2021)
      • 4.5.2 United States Bivalent Human Papillomavirus Vaccine Revenue by Players (2020, 2021 & 2022)
      • 4.5.3 United States Bivalent Human Papillomavirus Vaccine Sales by Players (2020, 2021 & 2022)

    5 Global Bivalent Human Papillomavirus Vaccine Market Size by Region

    • 5.1 Global Bivalent Human Papillomavirus Vaccine Market Size by Region: 2017 VS 2022 VS 2028
    • 5.2 Global Bivalent Human Papillomavirus Vaccine Market Size in Volume by Region (2017-2028)
      • 5.2.1 Global Bivalent Human Papillomavirus Vaccine Sales in Volume by Region: 2017-2022
      • 5.2.2 Global Bivalent Human Papillomavirus Vaccine Sales in Volume Forecast by Region (2023-2028)
    • 5.3 Global Bivalent Human Papillomavirus Vaccine Market Size in Value by Region (2017-2028)
      • 5.3.1 Global Bivalent Human Papillomavirus Vaccine Sales in Value by Region: 2017-2022
      • 5.3.2 Global Bivalent Human Papillomavirus Vaccine Sales in Value by Region: 2023-2028

    6 Segment in Region Level & Country Level

    • 6.1 North America
      • 6.1.1 North America Bivalent Human Papillomavirus Vaccine Market Size YoY Growth 2017-2028
      • 6.1.2 North America Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.1.3 United States
      • 6.1.4 Canada
    • 6.2 Asia-Pacific
      • 6.2.1 Asia-Pacific Bivalent Human Papillomavirus Vaccine Market Size YoY Growth 2017-2028
      • 6.2.2 Asia-Pacific Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Region (2017, 2022 & 2028)
      • 6.2.3 China
      • 6.2.4 Japan
      • 6.2.5 South Korea
      • 6.2.6 India
      • 6.2.7 Australia
      • 6.2.8 China Taiwan
      • 6.2.9 Indonesia
      • 6.2.10 Thailand
      • 6.2.11 Malaysia
    • 6.3 Europe
      • 6.3.1 Europe Bivalent Human Papillomavirus Vaccine Market Size YoY Growth 2017-2028
      • 6.3.2 Europe Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.3.3 Germany
      • 6.3.4 France
      • 6.3.5 U.K.
      • 6.3.6 Italy
      • 6.3.7 Russia
    • 6.4 Latin America
      • 6.4.1 Latin America Bivalent Human Papillomavirus Vaccine Market Size YoY Growth 2017-2028
      • 6.4.2 Latin America Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.4.3 Mexico
      • 6.4.4 Brazil
      • 6.4.5 Argentina
      • 6.4.6 Colombia
    • 6.5 Middle East and Africa
      • 6.5.1 Middle East and Africa Bivalent Human Papillomavirus Vaccine Market Size YoY Growth 2017-2028
      • 6.5.2 Middle East and Africa Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.5.3 Turkey
      • 6.5.4 Saudi Arabia
      • 6.5.5 UAE

    7 Company Profiles

    • 7.1 Merck & Co., Inc.
      • 7.1.1 Merck & Co., Inc. Corporation Information
      • 7.1.2 Merck & Co., Inc. Description and Business Overview
      • 7.1.3 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.1.4 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.1.5 Merck & Co., Inc. Recent Development
    • 7.2 GSK
      • 7.2.1 GSK Corporation Information
      • 7.2.2 GSK Description and Business Overview
      • 7.2.3 GSK Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.2.4 GSK Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.2.5 GSK Recent Development
    • 7.3 INNOVAX
      • 7.3.1 INNOVAX Corporation Information
      • 7.3.2 INNOVAX Description and Business Overview
      • 7.3.3 INNOVAX Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.3.4 INNOVAX Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.3.5 INNOVAX Recent Development
    • 7.4 ZSSW
      • 7.4.1 ZSSW Corporation Information
      • 7.4.2 ZSSW Description and Business Overview
      • 7.4.3 ZSSW Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.4.4 ZSSW Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.4.5 ZSSW Recent Development
    • 7.5 HUMANWELL HEALTHCARE
      • 7.5.1 HUMANWELL HEALTHCARE Corporation Information
      • 7.5.2 HUMANWELL HEALTHCARE Description and Business Overview
      • 7.5.3 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.5.4 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.5.5 HUMANWELL HEALTHCARE Recent Development
    • 7.6 WALVAX
      • 7.6.1 WALVAX Corporation Information
      • 7.6.2 WALVAX Description and Business Overview
      • 7.6.3 WALVAX Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.6.4 WALVAX Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.6.5 WALVAX Recent Development
    • 7.7 Serum Institute of India
      • 7.7.1 Serum Institute of India Corporation Information
      • 7.7.2 Serum Institute of India Description and Business Overview
      • 7.7.3 Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2017-2022)
      • 7.7.4 Serum Institute of India Bivalent Human Papillomavirus Vaccine Products Offered
      • 7.7.5 Serum Institute of India Recent Development

    8 Industry Chain and Sales Channels Analysis

    • 8.1 Bivalent Human Papillomavirus Vaccine Industry Chain Analysis
    • 8.2 Bivalent Human Papillomavirus Vaccine Key Raw Materials
      • 8.2.1 Key Raw Materials
      • 8.2.2 Bivalent Human Papillomavirus Vaccine Distributors
    • 8.3 Bivalent Human Papillomavirus Vaccine Production Mode & Process
    • 8.4 Bivalent Human Papillomavirus Vaccine Sales and Marketing
      • 8.4.1 Bivalent Human Papillomavirus Vaccine Sales Channels
      • 8.4.2 Bivalent Human Papillomavirus Vaccine Distributors
    • 8.5 Bivalent Human Papillomavirus Vaccine Customers

    9 Research Findings and Conclusion

      10 Appendix

      • 10.1 Research Methodology
        • 10.1.1 Methodology/Research Approach
        • 10.1.2 Data Source
      • 10.2 Author Details

      Summary:

      Market Analysis and Insights: Global and United States Bivalent Human Papillomavirus Vaccine Market
      This report focuses on global and United States Bivalent Human Papillomavirus Vaccine market, also covers the segmentation data of other regions in regional level and county level.
      Due to the COVID-19 pandemic, the global Bivalent Human Papillomavirus Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, HPV16 accounting for % of the Bivalent Human Papillomavirus Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, 9-16 Years Old was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
      In United States the Bivalent Human Papillomavirus Vaccine market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
      Global Bivalent Human Papillomavirus Vaccine Scope and Market Size
      Bivalent Human Papillomavirus Vaccine market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Bivalent Human Papillomavirus Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
      For United States market, this report focuses on the Bivalent Human Papillomavirus Vaccine market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
      Segment by Type, the Bivalent Human Papillomavirus Vaccine market is segmented into
      HPV16
      HPV18
      Segment by Application, the Bivalent Human Papillomavirus Vaccine market is segmented into
      9-16 Years Old
      16-20 Years Old
      20-26 Years Old
      26-45 Years Old
      Regional and Country-level Analysis
      By Region
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Landscape and Bivalent Human Papillomavirus Vaccine Market Share Analysis
      Bivalent Human Papillomavirus Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Bivalent Human Papillomavirus Vaccine business, the date to enter into the Bivalent Human Papillomavirus Vaccine market, Bivalent Human Papillomavirus Vaccine product introduction, recent developments, etc.
      The major vendors covered:
      Merck & Co., Inc.
      GSK
      INNOVAX
      ZSSW
      HUMANWELL HEALTHCARE
      WALVAX
      Serum Institute of India
      Buy now